Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations.
Deschamps R, Papeix C, Ayrignac X, Bourre B, Ciron J, Cohen M, Collongues N, Deiva K, Durand Dubief F, Laplaud DA, Maillart E, Michel L, Pique J, Ruet A, Thouvenot E, Zéphir H, Marignier R, Audoin B. Deschamps R, et al. Among authors: maillart e. Rev Neurol (Paris). 2024 Oct;180(8):711-714. doi: 10.1016/j.neurol.2024.06.003. Epub 2024 Jul 4. Rev Neurol (Paris). 2024. PMID: 38969609 No abstract available.
[Susac syndrome: study of five cases].
Maillart E, Deschamps R, Moulignier A, Vignal-Clermont C, Obadia M, Le Mer Y, Laloum L, Gout O. Maillart E, et al. Rev Neurol (Paris). 2009 Jun-Jul;165(6-7):575-82. doi: 10.1016/j.neurol.2008.10.022. Epub 2009 Jan 4. Rev Neurol (Paris). 2009. PMID: 19124141 French.
Efficacy of rituximab in refractory neuromyelitis optica.
Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R; OFSEP and CFSEP. Collongues N, et al. Among authors: maillart e. Mult Scler. 2016 Jun;22(7):955-9. doi: 10.1177/1352458515602337. Epub 2015 Sep 11. Mult Scler. 2016. PMID: 26362900
Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders.
Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Vukusic S, Zephir H, Marignier R, Collongues N; NOMADMUS group, under the aegis of OFSEP, SFSEP. Ciron J, et al. Among authors: maillart e. Rev Neurol (Paris). 2018 Apr;174(4):255-264. doi: 10.1016/j.neurol.2017.11.005. Epub 2018 Mar 30. Rev Neurol (Paris). 2018. PMID: 29606320 Review. English.
Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients.
Shor N, Aboab J, Maillart E, Lecler A, Bensa C, Le Guern G, Grunbaum S, Marignier R, Papeix C, Heron E, Gout O, Savatovsky J, Galanaud D, Vignal C, Touitou V, Deschamps R. Shor N, et al. Among authors: maillart e. Eur J Neurol. 2020 Feb;27(2):384-391. doi: 10.1111/ene.14089. Epub 2019 Oct 20. Eur J Neurol. 2020. PMID: 31532865
MSCopilot, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests.
Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, Donzé C, Gallien P, De Sèze J, Bourre B, Moreau T, Louapre C, Mayran P, Bieuvelet S, Vallée M, Bertillot F, Klaeylé L, Argoud AL, Zinaï S, Tourbah A. Maillart E, et al. Eur J Neurol. 2020 Mar;27(3):429-436. doi: 10.1111/ene.14091. Epub 2019 Oct 19. Eur J Neurol. 2020. PMID: 31538396 Clinical Trial.
Evaluation of efficacy and tolerability of first-line therapies in NMOSD.
Poupart J, Giovannelli J, Deschamps R, Audoin B, Ciron J, Maillart E, Papeix C, Collongues N, Bourre B, Cohen M, Wiertlewski S, Outteryck O, Laplaud D, Vukusic S, Marignier R, Zephir H; NOMADMUS study group. Poupart J, et al. Among authors: maillart e. Neurology. 2020 Apr 14;94(15):e1645-e1656. doi: 10.1212/WNL.0000000000009245. Epub 2020 Mar 13. Neurology. 2020. PMID: 32170036
208 results